In conclusion, our comprehensive pan-cancer analysis demonstrated that BUB1B is aberrantly expressed across various cancer types, with its expression levels significantly associated with clinicopathological characteristics and patient prognosis, particularly in lung adenocarcinoma. Here, BUB1B is linked to lung adenocarcinoma.